SLC5A2 and chronic kidney disease: Actually, the rapidly emerging evidence favoring SGLT2 inhibition means that high-risk CKD patients need to be identified early in the course of their disease, especially those with proteinuria and preserved kidney function in whom there is now an opportunity to slow down the trajectory of GFR decline [20].